OncoMatch/Clinical Trials/NCT06940180
Toripalimab With Chemotherapy for Sinus Cancer
Is NCT06940180 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Toripalimab and Carboplatin for sinonasal cancer.
Treatment: Toripalimab · Carboplatin · Docetaxel · Cisplatin — The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers. The names of the study drugs used in this research study are: * Toripalimab (a type of monoclonal antibody) * Carboplatin (a type of antineoplastic agent) * Docetaxel (a type of antineoplastic agent) * Cisplatin (a type of antineoplastic agent)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T2, N1-3 III, T3, ANY N III, T3, ANY N IVA, T3, ANY N IVB, T4, ANY N IVA, T4, ANY N IVB (AJCC/UICC 8th edition TNM)
Excluded: Stage IVC
clinical stage disease as defined below using the 8th (2017) edition of the tumor, node, metastasis (TNM) staging system by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC): * T2, N1-3 III * T3, any N III, IVA, IVB * T4, any N IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1 therapy or other agent directed to another stimulatory or co-inhibitory T-cell receptor
Has received prior therapy with an anti-PD-1/L1 agent or any other agent directed to another stimulatory or co-inhibitory T-cell receptor
Lab requirements
Blood counts
Absolute neutrophil count ≥1000/mcL; Platelets ≥100
Kidney function
Creatinine ≤institutional ULN or GFR of ≥50 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
Liver function
Total bilirubin ≤institutional upper limit of normal (ULN); AST(SGOT) / ALT (SGPT) ≤3x ULN
Participants must have adequate organ and marrow function as defined below: * Absolute neutrophil count ≥1000/mcL * Platelets ≥100 * Total bilirubin ≤institutional upper limit of normal (ULN) * AST(SGOT) / ALT (SGPT) ≤3x ULN * Creatinine ≤institutional ULN or GFR of ≥50 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06940180 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1/PD-L1 therapy or other agent directed to another stimulatory or co-inhibitory T-cell receptor disqualifies patients from enrollment.
What disease stage is eligible?
Stage T2, N1-3 III or T3, ANY N III or T3, ANY N IVA or T3, ANY N IVB or T4, ANY N IVA or T4, ANY N IVB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages